Learn about the latest trends and activities through our blog posts.
Illinois has enacted HB 3631, pro-pharmacy legislation sponsored by Senator Simmons. The new law prohibits pharmacy benefit managers from retaliating against pharmacists for disclosing information in government proceedings if they have reasonable cause to believe that the disclosed information is evidence of a violation of a state or federal law, rule, or regulation.
Read MorePresident Biden signed an executive order on August 9, 2023, that will regulate certain U.S. investments in countries of concern in entities engaged in activities involving sensitive technologies critical to national security. The order specifically targets investments in semiconductors and microelectronics, quantum information technologies, and artificial intelligence.
Read MoreTechnology companies are constantly collecting and using personal data. This data can include everything from names and addresses to browsing history and financial information. As technology companies collect more data, the importance of privacy becomes even more critical.
Read MoreH.R. 3831, the AI Disclosure Act of 2023, is a bill that would require companies that use artificial intelligence (AI) to disclose certain information about their use of AI. This information would include the purpose of the AI system, the data that the AI system is trained on, the algorithms that the AI system uses, and the potential risks and benefits of the AI system. The bill would also create a new agency within the Federal Trade Commission (FTC) to oversee the implementation of the law.
Read MoreJohnson and Johnson has filed a lawsuit in New Jersey federal district court, arguing that the new powers granted to Medicare to negotiate drug prices violates the First and Fifth Amendments of the U.S. Constitution. Medicare’s new power to negotiate comes from the recently enacted Inflation Reduction Act (IRA). Earlier suits by Merck, Bristol Myers Squibb, the U.S. Chamber of Commerce and PhRMA have made similar arguments.
Read MoreThis week the Biden Administration secured voluntary commitments from seven leading artificial intelligence (AI) companies, including Amazon, Anthropic, Google, Inflection, Meta, Microsoft, and OpenAI, to promote the safe, secure, and transparent development of AI technology.
Read MorePrivacy has emerged as a critical issue in the digital age, prompting increased scrutiny and regulation. In New York, a hub for technology and healthcare industries, privacy trends have been shaping the legal and regulatory landscape. This blog post will explore the evolving privacy trends in New York and delve into how Lanton Law can help tech and healthcare companies navigate complex privacy laws and develop effective legal and regulatory strategies.
Read MoreWhen it comes to navigating the complex world of lobbying, choosing the right lobbyist will make all the difference. Lanton Law offers a unique approach that has proven to be highly effective in driving positive change.
Read MoreLanton Law was quoted in Pharmacy Times article titled “Mifepristone Has its Day in Court.” The article discusses the drug amid its backdrop in the U.S. Supreme Court.
Read MoreLanton Law was on Beacon Hill this week advocating for pharmacy issues.
Read MoreLanton Law was quoted in the Pharmacy Times article titled “FDA Approves First Nonprescription Daily Birth Control Pill.”
Read MoreLanton Law speak with Pharmacy Times about the Supreme Court’s decision on Mifepristone.
Read MoreOn behalf of the Massachusetts Society of Health-System Pharmacists, we wrote an article advocating for the importance of health promotion screening in Massachusetts.
Read MoreWe were pleased to be invited to Orlando, Florida to speak with IDN with our presentation titled “Price, Innovation & Policy: What’s on the Horizon for the Industry.
Read MoreU.S. Senators John Cornyn (R-TX) and Richard Blumenthal (D-CT) have introduced the Affordable Prescriptions for Patients Act. The bill seen here seeks to lower drug prices by preventing bad actors’ anti-competitive use of patents to block generic and biosimilar competition from coming to market. The bill addresses two important issues such as product hopping and the patent dance.
Read MoreThe Drug Enforcement Administration has announced “proposed permanent rules for the prescribing of controlled medications via telemedicine, expanding patient access to critical therapies beyond the scheduled end of the COVID-19 public health emergency.
Read MoreRemote patient monitoring is an innovative way that healthcare providers are using to treat chronic and acute conditions. With COVID-19 spurring faster adoption of telehealth and RPM, the subject of RPM involves the connection of digital tools that record healthcare data that is reviewed by an off-site provider.
Read MoreAlthough the FDA has now allowed retail pharmacies to dispense mifepristone, a drug used for medicated abortions, questions still remain about the requirements for pharmacies and the availability of the drug. Lanton Law talks to Pharmacy Times in an interview about a post Dobbs world with mifepristone.
Read MoreWe have a new podcast with Professor Downing of the University of Washington School of Pharmacy. We discuss pharmacy provider status and the opportunities within pharmacy.
Read More
